AMBS' Business Model for MANF is to look for promising indications that can receive orphan designation, reducing the time and money needed to obtain final FDA approval. This makes the indication desirable for partnerships. As of today, RP seems to be ahead of Wolframs in getting orphan designation, but possibly not by much. Both RP and Wolframs have data coming out in prominent Journals this month. RP is likely to obtain orphan designation by this fall, and possibly wolframs too. Dr. Urana said this week that they are in talks with a Big Pharma regarding a partnership. That is AMBS' goal for both of these indications: a partnership this year with up front cash and milestone payments for future progress. Perhaps we get one partnership before up listing and the other partnership soon after up listing? These are nice catalysts for the stock price, in addition to the huge impact LymPro is going to have on our price in the coming weeks and months. Gerald was also seeking orphan status for Eltoprazine as well. Once Eltoprazine's trial gets firmed up I expect some grant from MJFF to help with funding. Gerald also indicated we would be hearing about more MANF indications, adding to the pipeline.
RR if Lympro creates status I will be surprised but hopeful. I have made it very clear to you Lympro is not my investment, The new player ELTO caught me off guard, thought it was going to be different direction towards PD I admit I missed that one, MANF is tracking as has been indicated, With Phenoguard and NuroPro in the background and the new Pharmaceutical that will be mentioned 4Q now we are understanding the investment.
cloveless: You don't believe LymPro's data to be announced this month is going to be impressive and bring us a partner that will pop us to a pps well over .20 -.30 cents by end of summer?
I agree with all you said. However, you omitted perhaps the most important part: MANPOWER. He has pulled together movers and shakers who wouldn't have made the move to AMBS without seeing the value of such a move. Their experience and know-how will be part and parcel of this Company's success. That is why I have invested.
You are absolutely right! I have never paid more attention to the "TALENT" of the "MANPOWER" in a company than I have in AMBS! I credit this to Gerald's Dad, John. He has been around the block a few times in the pharma world and knows what it takes to get things approved. Dr. Lowe also seems to know how to get drugs approved as quickly as possible. Incredible team.
He seems to have a very well executed business model that is not to rigid and with goals supported by data, research and foundations. This information that you posted is available to all who want to take the time and research the company. Shut out the white noise from crackpots and self proclaimed know it alls here and on Ihub. Set your investment goals and enjoy your returns.